Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

Gilead Sciences has signed its third acquisition deal since the start of the year, agreeing to buy Germany's Tubulis and its pipeline of antibody-drug conjugates (ADCs) for cancer. Assuming the ...

HHS Secretary Robert F Kennedy Jr has followed a court ruling that his controversial appointments to the CDC's Advisory Committee on Immunization Practices (ACIP) were unlawful by changing the panel's ...

Anthropic has continued its push into the healthcare sector by acquiring New York startup Coefficient Bio, a specialist in applying AI to drug discovery that was set up last year but until now has ...

Lunsekimig is one of a trio of clinical candidates that Sanofi is developing as successors to its big-selling IL-3 and IL-13 ...

Amgen's Tepezza became the first drug approved by the FDA for thyroid eye disease (TED) in 2020, and the company is now looking to extend its role with a new, more patient-friendly formulation. The ...

Neurocrine Biosciences has agreed a $2.9 billion deal to buy Soleno Therapeutics and its treatment for a rare, genetic form ...

By utilising augmented intelligence early, small and mid-sized companies can maximise their innovation potential, minimise ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US biotech Owkin. Financial ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...

Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...